A share price of Syndax Pharmaceuticals Inc [SNDX] is currently trading at $9.92, down -0.70%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SNDX shares have lost -0.70% over the last week, with a monthly amount glided 12.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on July 10, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $18. Previously, UBS started tracking the stock with Buy rating on October 24, 2024, and set its price target to $37. On June 28, 2024, Jefferies initiated with a Buy rating and assigned a price target of $37 on the stock. Scotiabank downgraded its rating to a Sector Perform and decreased its price target to $23 on January 31, 2024. Mizuho initiated its recommendation with a Buy and recommended $45 as its price target on December 22, 2023. BofA Securities started tracking with a Buy rating for this stock on October 25, 2023, and assigned it a price target of $29. In a note dated October 11, 2023, Goldman initiated an Buy rating and provided a target price of $30 on this stock.
Syndax Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $8.58 and $23.37. Currently, Wall Street analysts expect the stock to reach $26.5 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $9.92 at the most recent close of the market. An investor can expect a potential return of 167.14% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -7.87%, Pretax Profit Margin comes in at -7.58%, and Net Profit Margin reading is -7.58%. To continue investigating profitability, this company’s Return on Assets is posted at -0.52, Equity is -1.02 and Total Capital is -0.63.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.64 points at the first support level, and at 9.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.12, and for the 2nd resistance point, it is at 10.32.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Syndax Pharmaceuticals Inc [NASDAQ:SNDX] is 5.80. As well, the Quick Ratio is 5.75, while the Cash Ratio is 1.63. Considering the valuation of this stock, the price to sales ratio is 19.52, the price to book ratio is 3.97.
Transactions by insiders
Recent insider trading involved Goldan Keith A., Chief Financial Officer, that happened on Jul 16 ’25 when 1296.0 shares were sold. Chief Executive Officer, Metzger Michael A completed a deal on Jul 16 ’25 to sell 7534.0 shares. Meanwhile, Officer Goldan Keith A. bought 1296.0 shares on Jul 16 ’25.
